The Case for Priority: Why HSV Deserves the Highest Research Funding of All STIs

We need to stop asking for "better" treatment and start demanding priority status.

When you look at the current landscape of sexually transmitted infections, the funding allocation is completely misaligned with the actual patient burden. For decades, HIV has (rightfully) dominated the funding conversation, followed by HPV. But in 2025, the medical reality has changed, and the funding model has not caught up.

Here is the objective, clinical argument for why HSV should now be the #1 priority for STI research funding:

1. The "Management vs. Uncertainty" Gap

In modern medicine, we measure disease burden not just by mortality, but by Quality of Life (QoL).

• HIV: With modern ART (antiretroviral therapy), HIV is a predictable, chronic condition. Patients who are "Undetectable" have zero risk of sexual transmission (U=U). They have medical certainty.

• HSV: We live in permanent medical uncertainty. Even on daily antivirals, we have a risk of transmission. We cannot predict our next outbreak. We cannot predict if our partners will be asymptomatic or suffer severe complications.

• The Burden: Psychologically, humans handle "bad news" better than they handle "uncertainty." The anxiety of harming a partner creates a psychological burden for HSV-2 patients that now arguably exceeds that of medically managed HIV.

2. The Economic Case (The "Hidden" Cost)

Funding agencies look at "Quality Adjusted Life Years" (QALYs). HSV is a massive drain on this metric.

• Mental Health Costs: The depression, anxiety, and psychosexual dysfunction associated with an HSV diagnosis are clinically significant. We are treating millions of people for anxiety solely because of a skin virus that science has neglected.

3. The "Missing Link" in Prevention

• HPV: We have a vaccine. The problem is solved for future generations.

• Hep B: We have a vaccine.

• Hep C/Chlamydia/Gonorrhea: We have cures.

• HSV-2: We have nothing that stops infection or transmission completely. It is the only highly prevalent STI where a patient has no tool to guarantee their partner’s safety. This "prevention gap" alone justifies shifting the bulk of STI research funding toward a functional cure or vaccine for Herpes.